1. Home
  2. NAMS vs PENN Comparison

NAMS vs PENN Comparison

Compare NAMS & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • PENN
  • Stock Information
  • Founded
  • NAMS 2019
  • PENN 1972
  • Country
  • NAMS Netherlands
  • PENN United States
  • Employees
  • NAMS N/A
  • PENN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • PENN Hotels/Resorts
  • Sector
  • NAMS Health Care
  • PENN Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • PENN Nasdaq
  • Market Cap
  • NAMS 2.7B
  • PENN 3.0B
  • IPO Year
  • NAMS N/A
  • PENN 1994
  • Fundamental
  • Price
  • NAMS $23.33
  • PENN $20.13
  • Analyst Decision
  • NAMS Strong Buy
  • PENN Buy
  • Analyst Count
  • NAMS 7
  • PENN 21
  • Target Price
  • NAMS $38.17
  • PENN $23.38
  • AVG Volume (30 Days)
  • NAMS 538.3K
  • PENN 5.2M
  • Earning Date
  • NAMS 02-06-2025
  • PENN 02-13-2025
  • Dividend Yield
  • NAMS N/A
  • PENN N/A
  • EPS Growth
  • NAMS N/A
  • PENN N/A
  • EPS
  • NAMS N/A
  • PENN N/A
  • Revenue
  • NAMS $33,594,000.00
  • PENN $6,304,500,000.00
  • Revenue This Year
  • NAMS $131.53
  • PENN $5.90
  • Revenue Next Year
  • NAMS N/A
  • PENN $5.54
  • P/E Ratio
  • NAMS N/A
  • PENN N/A
  • Revenue Growth
  • NAMS 78.77
  • PENN N/A
  • 52 Week Low
  • NAMS $15.19
  • PENN $13.50
  • 52 Week High
  • NAMS $27.29
  • PENN $24.57
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 44.28
  • PENN 53.12
  • Support Level
  • NAMS $23.17
  • PENN $19.67
  • Resistance Level
  • NAMS $26.71
  • PENN $20.80
  • Average True Range (ATR)
  • NAMS 0.94
  • PENN 1.10
  • MACD
  • NAMS -0.40
  • PENN 0.18
  • Stochastic Oscillator
  • NAMS 23.65
  • PENN 73.11

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About PENN PENN Entertainment Inc.

Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 89% of total sales in 2023; 11% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.

Share on Social Networks: